Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …

Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Background: Atrial fibrillation (AF) causes a significant health and economic burden to the
Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better …

Background Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …

Objective The goal of this study was to assess the differences between an ex ante and an ex
post cost-effectiveness analysis of Dabigatran etexilate vs VKAs for the prevention of …

This article provides an overview of the clinical profile of oral dabigatran etexilate
(Pradaxa®, Pradax™)[hereafter referred to as dabigatran] when used for the prevention of …

Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for …

Background A number of models exploring the cost-effectiveness of dabigatran versus
warfarin for stroke prevention in atrial fibrillation have been published. These studies found …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …